A mounting body of research points to cerebrovascular dysfunction as a fundamental element in the pathophysiology of Parkinson’s disease (PD). In the current feasibility study, blood-oxygen-level-dependent (BOLD) MRI was used to measure cerebrovascular reactivity (CVR) in response to hypercapnia in 26 PD patients and 16 healthy controls (HC), and aimed to find a multivariate pattern specific to PD. Whole-brain maps of CVR amplitude (i.e., magnitude of response to CO2) and latency (i.e., time to reach maximum amplitude) were computed, which were further analyzed using scaled sub-profile model principal component analysis (SSM-PCA) with leave-one-out cross-validation. A meaningful pattern based on CVR latency was identified, which was named the PD CVR pattern (PD-CVRP). This pattern was characterized by relatively increased latency in basal ganglia, sensorimotor cortex, supplementary motor area, thalamus and visual cortex, as well as decreased latency in the cerebral white matter, relative to HC. There were no significant associations with clinical measures, though sample size may have limited our ability to detect significant associations. In summary, the PD-CVRP highlights the importance of cerebrovascular dysfunction in PD, and may be a potential biomarker for future clinical research and practice.
RymanSGPostonKL.MRI biomarkers of motor and non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord2019;
73: 85–93.
2.
CassidyCMZuccaFAGirgisRR, et al.
Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain. Proc Natl Acad Sci U S A2019;
116: 5108–5117.
3.
SulzerDCassidyCHorgaG, et al.
Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson’s disease. NPJ Park Dis2018;
4: 11.
4.
FoltynieTBrayneCBarkerRA.The heterogeneity of idiopathic Parkinson’s disease. J Neurol2002;
249: 138–145.
5.
JellingerKA.Neuropathobiology of non-motor symptoms in Parkinson disease. J Neural Transm (Vienna)2015;
122: 1429–1440.
6.
SchapiraAVChaudhuriKRJennerP.Non-motor features of Parkinson disease. Nat Rev Neurosci2017;
18: 435–450.
7.
BidesiNSRVang AndersenIWindhorstAD, et al.
The role of neuroimaging in Parkinson’s disease. J Neurochem2021;
159: 660–689.
8.
ChahineLMMerchantKSiderowfA, et al.
Proposal for a biologic staging system of Parkinson’s disease. J Parkinsons Dis2023;
13: 297–309.
9.
MadhyasthaTMAskrenMKBoordP, et al.
Cerebral perfusion and cortical thickness indicate cortical involvement in mild Parkinson’s disease. Mov Disord2015;
30: 1893–1900.
10.
Al-BachariSVidyasagarREmsleyHCA, et al.
Structural and physiological neurovascular changes in idiopathic Parkinson’s disease and its clinical phenotypes. J Cereb Blood Flow Metab2017;
37: 3409–3421.
11.
TeuneLKRenkenRJde JongBM, et al.
Parkinson’s disease-related perfusion and glucose metabolic brain patterns identified with PCASL-MRI and FDG-PET imaging. NeuroImage Clin2014;
5: 240–244.
12.
FeiginAAntoniniAFukudaM, et al.
Tc‐99m ethylene cysteinate dimer SPECT in the differential diagnosis of Parkinsonism. Mov Disord off Disord2002;
17: 1265–1270.
13.
KamagataKMotoiYHoriM, et al.
Posterior hypoperfusion in Parkinson’s disease with and without dementia measured with arterial spin labeling MRI. J Magn Reson Imaging2011;
33: 803–807.
14.
MelzerTRWattsRMacAskillMR, et al.
Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson’s disease. Brain2011;
134: 845–855.
15.
Fernández-SearaMAMengualEVidorretaM, et al.
Cortical hypoperfusion in Parkinson’s disease assessed using arterial spin labeled perfusion MRI. Neuroimage2012;
59: 2743–2750.
16.
Al-BachariSParkesLMVidyasagarR, et al.
Arterial spin labelling reveals prolonged arterial arrival time in idiopathic Parkinson’s disease. NeuroImage Clin2014;
6: 1–8.
17.
SyrimiZJVojtisekLEliasovaI, et al.
Arterial spin labelling detects posterior cortical hypoperfusion in non-demented patients with Parkinson’s disease. J Neural Transm (Vienna)2017;
124: 551–557.
18.
PelizzariLDi TellaSRossettoF, et al.
Parietal perfusion alterations in Parkinson’s disease patients without dementia. Front Neurol2020;
11: 562.
19.
JoshiDPrasadSSainiJ, et al.
Role of arterial spin labeling (ASL) images in Parkinson’s disease (PD): a systematic review. Acad Radiol2022;
30: 1695–1708.
20.
IadecolaC.The neurovascular unit coming of age: a journey through neurovascular coupling in health and disease. Neuron2017;
96: 17–42.
21.
de la TorreJC.Are major dementias triggered by poor blood flow to the brain? Theoretical considerations. J Alzheimers Dis2017;
57: 353–371.
22.
WillieCKTzengYFisherJA, et al.
Integrative regulation of human brain blood flow. J Physiol2014;
592: 841–859.
23.
SchaefferSIadecolaC.Revisiting the neurovascular unit. Nat Neurosci2021;
24: 1198–1209.
24.
LiuPDe VisJBLuH.Cerebrovascular reactivity (CVR) MRI with CO2 challenge: a technical review. Neuroimage2019;
187: 104–115.
25.
RymanSGShaffNDoddA, et al.
Reduced and delayed cerebrovascular reactivity in patients with Parkinson’s disease. Mov Disord2023;
38: 1262–1272.
26.
HabeckCFosterNLPerneczkyR, et al.
Multivariate and univariate neuroimaging biomarkers of Alzheimer’s disease. Neuroimage2008;
40: 1503–1515.
27.
WooC-WChangLJLindquistMA, et al.
Building better biomarkers: brain models in translational neuroimaging. Nat Neurosci2017;
20: 365–377.
28.
HabeckCSternY.Multivariate data analysis for neuroimaging data: overview and application to Alzheimer’s disease. Cell Biochem Biophys2010;
58: 53–67.
29.
HenningsACCooperSELewis-PeacockJA, et al.
Pattern analysis of neuroimaging data reveals novel insights on threat learning and extinction in humans. Neurosci Biobehav Rev2022;
142: 104918.
30.
MwangiBTianTSSoaresJC.A review of feature reduction techniques in neuroimaging. Neuroinformatics2014;
12: 229–244.
31.
MoellerJRStrotherSC.A regional covariance approach to the analysis of functional patterns in positron emission tomographic data. J Cereb Blood Flow Metab1991;
11: A121–A135.
32.
SpetsierisPGEidelbergD.Scaled subprofile modeling of resting state imaging data in Parkinson’s disease: methodological issues. Neuroimage2011;
54: 2899–2914.
33.
McKeownMJMakeigSBrownGG, et al.
Analysis of fMRI data by blind separation into independent spatial components. Hum Brain Mapp1998;
6: 160–188.
34.
SchindlbeckKAEidelbergD.Network imaging biomarkers: Insights and clinical applications in Parkinson’s disease. Lancet Neurol2018;
17: 629–640.
35.
PostonKLEidelbergD.Network biomarkers for the diagnosis and treatment of movement disorders. Neurobiol Dis2009;
35: 141–147.
36.
PostonKLEidelbergD.18F-Fluorodeoxyglucose PET in the evaluation of Parkinson disease. PET Clin2010;
5: 55–64.
37.
MaYHuangCDykeJP, et al.
Parkinson’s disease spatial covariance pattern: noninvasive quantification with perfusion MRI. J Cereb Blood Flow Metab2010;
30: 505–509.
38.
RaneSKohNOakleyJ, et al.
Arterial spin labeling detects perfusion patterns related to motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord2020;
76: 21–28.
39.
VoASakoWFujitaK, et al.
Parkinson’s disease‐related network topographies characterized with resting state functional MRI. Hum Brain Mapp2017;
38: 617–630.
40.
MelesSKOertelWHLeendersKL.Circuit imaging biomarkers in preclinical and prodromal Parkinson’s disease. Mol Med2021;
27: 111–114.
41.
GoetzCGTilleyBCShaftmanSR, et al.
Movement disorder society‐sponsored revision of the unified Parkinson’s disease rating scale (MDS‐UPDRS): scale presentation and clinimetric testing results. Mov Disord off Disord2008;
23: 2129–2170.
42.
TomlinsonCLStoweRPatelS, et al.
Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord2010;
25: 2649–2653.
43.
GibbonsCHSchmidtPBiaggioniI, et al.
The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol2017;
264: 1567–1582.
44.
FreemanRWielingWAxelrodFB, et al.
Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton Neurosci Basic Neurosci2011;
161: 46–48.
45.
LitvanIGoldmanJGTrösterAI, et al.
Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: movement disorder society task force guidelines. Mov Disord2012;
27: 349–356.
46.
ReitanRM.Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills1958;
8: 271–276.
47.
SmithA.Symbol digit modalities test (SDMT) manual (revised) Western psychological services. Los Angeles1973.
48.
IvanovaISalmonDPGollanTH.The multilingual naming test in Alzheimer’s disease: clues to the origin of naming impairments. J Int Neuropsychol Soc2013;
19: 272–283.
49.
BentonALVarneyNRHamsherK.Visuospatial judgment: a clinical test. Arch Neurol1978;
35: 364–367.
50.
BrandtJBenedictRHB.Hopkins verbal learning test–revised: Professional manual. Psychological Assessment Resources, 2001.
51.
BenedictRHBSchretlenDGroningerL, et al.
Revision of the brief visuospatial memory test: studies of normal performance, reliability, and validity. Psychol Assess1996;
8: 145–153.
52.
FleuryVPollakPGereJ, et al.
Levodopa does not change cerebral vasoreactivity in Parkinson’s disease. Mov Disord2013;
31: 1389–1397.
53.
LuHLiuPYezhuvathU, et al.
MRI mapping of cerebrovascular reactivity via gas inhalation challenges. J Vis Exp2014;
94: e52306.
54.
FisherJA.The CO2 stimulus for cerebrovascular reactivity: fixing inspired concentrations vs. targeting end-tidal partial pressures. J Cereb Blood Flow Metab2016;
36: 1004–1011.
55.
HarmsMPSomervilleLHAncesBM, et al.
Extending the human connectome project across ages: imaging protocols for the lifespan development and aging projects. Neuroimage2018;
183: 972–984.
56.
CoxR.AFNI: Software for analysis and visualization of functional magnetic resonance neuroimages. Comput Biomed Res1996;
29: 162–173.
PowerJDBarnesKASnyderAZ, et al.
Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. Neuroimage2012;
59: 2142–2154.
61.
LiuPHebrankACRodrigueKM, et al.
Age-related differences in memory-encoding fMRI responses after accounting for decline in vascular reactivity. Neuroimage2013;
78: 415–425.
62.
GolestaniAMWeiLLChenJJ.Quantitative mapping of cerebrovascular reactivity using resting-state BOLD fMRI: validation in healthy adults. Neuroimage2016;
138: 147–163.
63.
BirnRMSmithMAJonesTB, et al.
The respiration response function: the temporal dynamics of fMRI signal fluctuations related to changes in respiration. Neuroimage2008;
40: 644–654.
64.
ThomasBPLiuPParkDC, et al.
Cerebrovascular reactivity in the brain white matter: magnitude, temporal characteristics, and age effects. J Cereb Blood Flow Metab2014;
34: 242–247.
65.
MelesSKKokJGDe JongBM, et al.
The cerebral metabolic topography of spinocerebellar ataxia type 3. NeuroImage Clin2018;
19: 90–97.
66.
ItoSMardimaeAHanJ, et al.
Non‐invasive prospective targeting of arterial P in subjects at rest. J Physiol2008;
586: 3675–3682.
67.
MarkCISlessarevMItoS, et al.
Precise control of end‐tidal carbon dioxide and oxygen improves BOLD and ASL cerebrovascular reactivity measures. Magn Reson Med2010;
64: 749–756.
68.
HalaniSKwintaJBGolestaniAM, et al.
Comparing cerebrovascular reactivity measured using BOLD and cerebral blood flow MRI: the effect of basal vascular tension on vasodilatory and vasoconstrictive reactivity. Neuroimage2015;
110: 110–123.
69.
AkaikeH.Information theory and an extension of the maximum likelihood principle. In: H. Akaike, E. Parzen, K. Tanabe and G. Kitagawa (eds.),Selected papers of hirotugu akaike.
Berlin:
Springer, 1998, pp. 199–213.
70.
WenglerKHeXAbi-DarghamA, et al.
Reproducibility assessment of neuromelanin-sensitive magnetic resonance imaging protocols for region-of-interest and voxelwise analyses. Neuroimage2020;
208: 116457.
71.
PauliWMNiliANTyszkaJM.A high-resolution probabilistic in vivo atlas of human subcortical brain nuclei. Sci Data2018;
5: 180063.
72.
ShaffNErhardtENitschkeS, et al.
Comparison of automated and manual quantification methods for n euromelanin‐sensitive MRI in Parkinson’s disease. Hum Brain Mapp2023;
45: e26544.
73.
CohenADAgarwalMJagraAS, et al.
Longitudinal reproducibility of MR perfusion using 3D pseudocontinuous arterial spin labeling with Hadamard‐encoded multiple postlabeling delays. J Magn Reson Imaging2020;
51: 1846–1853.
74.
LeeYKoJChoiYE, et al.
Areas of white matter hyperintensities and motor symptoms of Parkinson disease. Neurology2020;
95: e291–e298.
75.
JainSGoldsteinDS.Cardiovascular dysautonomia in Parkinson disease: from pathophysiology to pathogenesis. Neurobiol Dis2012;
46: 572–580.
76.
OrimoSOzawaENakadeS, et al.
123I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson’s disease. J Neurol Neurosurg Psychiatry1999;
67: 189–194.
77.
TakiJNakajimaKHwangE-H, et al.
Peripheral sympathetic dysfunction in patients with Parkinson’s disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med2000;
27: 566–573.
78.
OrimoSSuzukiMInabaA, et al.
123I-MIBG myocardial scintigraphy for differentiating Parkinson’s disease from other neurodegenerative Parkinsonism: a systematic review and meta-analysis. Parkinsonism Relat Disord2012;
18: 494–500.
79.
HottaH.Neurogenic control of parenchymal arterioles in the cerebral cortex. Prog Brain Res2016;
225: 3–39.
80.
Ter LaanMVan DijkJMCEltingJWJ, et al.
Sympathetic regulation of cerebral blood flow in humans: a review. Br J Anaesth2013;
111: 361–367.
81.
KoepJLTaylorCECoombesJS, et al.
Autonomic control of cerebral blood flow: fundamental comparisons between peripheral and cerebrovascular circulations in humans. J Physiol2022;
600: 15–39.
82.
BohnenNIYarnallAJWeilRS, et al.
Cholinergic system changes in Parkinson’s disease: emerging therapeutic approaches. Lancet Neurol2022;
21: 381–392.
83.
XiaYEelesEFrippJ, et al.
Reduced cortical cholinergic innervation measured using [18F]-FEOBV PET imaging correlates with cognitive decline in mild cognitive impairment. NeuroImage Clin2022;
34: 102992.
84.
OkkelsNHorsagerJLabrador-EspinosaMA, et al.
Distribution of cholinergic nerve terminals in the aged human brain measured with [18F] FEOBV PET and its correlation with histological data. Neuroimage2023;
269: 119908.
85.
Van BeekAHEAClaassenJAHR.The cerebrovascular role of the cholinergic neural system in Alzheimer’s disease. Behav Brain Res2011;
221: 537–542.
86.
WongYCLukKPurtellK, et al.
Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?Mov Disord2019;
34: 1406–1422.
87.
SeldenNRGitelmanDRSalamon-MurayamaN, et al.
Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain a Brain1998;
121 (Pt 12): 2249–2257.
88.
BallingerECAnanthMTalmageDA, et al.
Basal forebrain cholinergic circuits and signaling in cognition and cognitive decline. Neuron2016;
91: 1199–1218.
89.
GlodzikLRandallCRusinekH, et al.
Cerebrovascular reactivity to carbon dioxide in Alzheimer’s disease. J Alzheimers Dis2013;
35: 427–440.
90.
Almanza-HurtadoAGuerraCPMartínez-ÁvilaMC, et al.
Hypercapnia from physiology to practice. Int J Clin Pract2022;
2022: 1–10.
91.
ÖzbayPSChangCPicchioniD, et al.
Contribution of systemic vascular effects to fMRI activity in white matter. Neuroimage2018;
176: 541–549.
92.
GoreJCLiMGaoY, et al.
Functional MRI and resting state connectivity in white matter-a mini-review. Magn Reson Imaging2019;
63: 1–11.
93.
HallerSZaharchukGThomasDL, et al.
Arterial spin labeling perfusion of the brain: emerging clinical applications. Radiology2016;
281: 337–356.
94.
PelizzariLLaganàMMRossettoF, et al.
Cerebral blood flow and cerebrovascular reactivity correlate with severity of motor symptoms in Parkinson’s disease. Ther Adv Neurol Disord2019;
12: 1756286419838354.
95.
MelesSKTangCCTeuneLK, et al.
Abnormal metabolic pattern associated with cognitive impairment in Parkinson’s disease: a validation study. J Cereb Blood Flow Metab2015;
35: 1478–1484.
96.
EckertTTangCEidelbergD.Assessment of the progression of Parkinson’s disease: a metabolic network approach. Lancet Neurol2007;
6: 926–932.
97.
MračkováMMarečekRMekyskaJ, et al.
Levodopa may modulate specific speech impairment in Parkinson’s disease: an fMRI study. J Neural Transm2023;
131: 181–187.
98.
HaslingerBErhardPKämpfeN, et al.
Event-related functional magnetic resonance imaging in Parkinson’s disease before and after levodopa. Brain2001;
124: 558–570.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
